Svelte technologies deliver exceptional clinical outcomes with procedural efficiency – benefitting patients, physicians, providers and payers.

Over the last 30-years treatment of most coronary artery disease has shifted from surgical bypass grafting in operating rooms to Percutaneous Coronary Intervention (PCI) in cath labs. Coronary artery stenting remains the primary mode of revascularization for PCI and is used in > 95% of cases1. An estimated 3.5 million stents are implanted annually world-wide, driving a $5+ billion and growing market2.

Although the percentage of patients diagnosed with chronic angina has remained stable, catheterization laboratory volume has surged as clinical indications for coronary stents continue to expand.

This is principally driven by:

  • Technological improvements in coronary stents and antithrombotic regimens which have made PCI much safer and reliable than a decade ago, and
  • More patients being referred for acute coronary syndromes (ACS) – ‘fast-tracking’ PCI improves ACS patient outcomes compared with medical management alone, as shown in several multicenter international trials3-5

Drug-eluting stents (DES) will remain the standard of care in the treatment of most coronary artery disease for years to come. However with interventional techniques and clinical outcomes increasingly converging, focus is now shifting towards:

  • Enhancing patient experience and
  • Maximizing procedural efficiency

Stent technologies must adapt to address the needs of the modern healthcare environment, particularly as PCI grows.

Svelte Technologies Address Today’s Healthcare Needs

Although stent technologies have improved over time, improvements have been iterative rather than transformational, focusing primarily on the enhancement of existing delivery systems and drug coatings.

Svelte Medical Systems was founded to establish a new paradigm in stenting,
one conveying benefits to all constituents of the modern healthcare environment.


Benefits Overview


Ultra-low profile yet highly deliverable Svelte drug-eluting stent platforms facilitate transradial intervention (TRI) and direct stenting, providing significant clincial and economic benefits which are well known. These, coupled with the exceptional safety and efficacy outcomes observed in Svelte clinical studies, allow Svelte state-of-the-art technologies to uniquely and universally impact the healthcare system.


Offering unsurpassed clinical outcomes and the unique ability to optimize utilization of cath lab resources, Svelte technologies benefit all constituents involved in coronary stenting:

Patients, Physicians, Providers and Payers.


  1. Fischell T. A new fixed-wire, ‘stent-on-a-wire’, very-low-profile stent delivery system – rationale, design and update. Interventional Cardiology, 2010;5:20-2.
  2. J.P. Morgan Equity Research, 2013 Interventional Cardiology Market Model.
  3. Bavry A et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized trials. J Am Coll Cardiol Intv. 2006;48(7):1319-1325.
  4. Nishigaki K et al. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively  than initial medical therapy only among patients with low-risk coronary artery disease. J Am Coll Cardiol Intv. 2008;1(5):469-479.
  5. Mehta S et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360:2165-2175.


CAUTION: The law restricts SLENDER IDS and DIRECT RX to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. SLENDER IDS and DIRECT RX are CE Mark certified but not available for sale in the US.